M. Brader

发表

The allosteric transition of the insulin hexamer is modulated by homotropic and heterotropic interactions.

M. Dunn, W. E. Choi, N. Kaarsholm, 1993, Biochemistry.

Simultaneous Multiple Sample Light Scattering (SMSLS) for Continuous Monitoring of Protein Aggregation

Michael F. Drenski, W. Reed, M. Brader, 2015 .

Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: a prototypical example of biopharmaceutical aggregation.

B. Thomas, M. Brader, A. Pekar, 2005, Journal of pharmaceutical sciences.

Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development.

E. Baker, T. Laue, J. Carpenter, 2017, Journal of pharmaceutical sciences.

Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity.

Shujun Bai, M. Brader, Alex Buko, 2011, Biotechnology and bioengineering.

Effects of submicron particles on formation of micron-sized particles during long-term storage of an interferon-β-1a solution.

M. Brader, Shujun Bai, Yogapriya Murugesan, 2013, Journal of pharmaceutical sciences.

Encapsulation state of messenger RNA inside lipid nanoparticles

Z. Zhou, W. Hui, M. Brader, 2021, Biophysical journal.

Characterization of the R-state insulin hexamer and its derivatives. The hexamer is stabilized by heterotropic ligand binding interactions.

M. Dunn, N. Kaarsholm, M. Brader, 1991, Biochemistry.

Physicochemical basis for the rapid time‐action of LysB28ProB29‐insulin: Dissociation of a protein‐ligand complex

J. M. Beals, D. Brems, J. Beals, 1996, Protein science : a publication of the Protein Society.

Structural studies of a crystalline insulin analog complex with protamine by atomic force microscopy.

M. Ward, C. Yip, M. Brader, 2000, Biophysical journal.

A Biopharmaceutical Perspective on Higher-Order Structure and Thermal Stability of mRNA Vaccines

M. Brader, Jessica M. Banks, M. Kloczewiak, 2022, Molecular pharmaceutics.

UV-absorbance, fluorescence and FT-IR spectroscopy in biopharmaceutical development

M. Brader, 2020 .

The Value of UV, Fluorescence, and FTIR Spectroscopy in Biopharmaceutical Development

M. Brader, 2015 .

Angle-dependent effects in DLS measurements of polydisperse particles

W. Reed, M. Brader, Lin Jin, 2021, Measurement Science and Technology.

A chromophoric study of zinc coordination and conformer selectivity of the human insulin hexamer in solution

M. Brader, 2002 .

Ligand Perturbation Effects on a Pseudotetrahedral Co(II)(His)3-Ligand Site

S. Harnung, M. Dunn, N. Kaarsholm, 1997, The Journal of Biological Chemistry.

The T to R transition in the copper(II)-substituted insulin hexamer. Anion complexes of the R-state species exhibiting type 1 and type 2 spectral characteristics.

M. Dunn, D. Borchardt, M. Brader, 1992, Biochemistry.

Synthetic, spectroscopic and X-ray crystallographic studies on phenylcyanamidocopper(I) complexes

E. Baker, J. Waters, P. Healy, 1991 .

Synthetic, spectroscopic, and X-ray crystallographic studies on phenylcyanamidocopper(II) complexes. The characterization of three different co-ordination modes for phenylcyanamide anions

E. Baker, M. Brader, E. Ainscough, 1990 .

Copper (II) promoted desulphurization of N-phenylthiourea. The synthesis and X-ray structure of [{Cu(bipy)(pc)2}2] (bipy=2,2'-bipyridine, pc=phenylcyanamide)

E. Baker, M. Brader, E. Ainscough, 1989 .

Protein Aggregation in Pharmaceutical Biotechnology

M. Brader, 2014 .

Ligand effects on the blue copper site. Spectroscopic studies of an insulin-stabilized copper(II) chromophore incorporating an exogenous thiolate ligand

M. Dunn, D. Borchardt, M. Brader, 1992 .

Calcium binding to a factor ix Fc fusion protein and effects on higher-order structure.

S. Berkowitz, M. Brader, Shufeng Bai, 2011, Journal of pharmaceutical sciences.

Copper(II)-promoted oxidation of mercaptocarboxylic acids. The characterization of disulphide- and oxalate-containing products. Crystal structures of [{Cu(bipy)(2,2′-dtdp)}n]·3nH2O and [{Cu(bipy)(3,3′-dtdp)}n]·2nH2O (bipy = 2,2′-bipyridine, dtdp = dithiodipropanoate)

E. Baker, M. Brader, David A. Lewandoski, 1990 .

Charge-transfer spectra of structurally characterized mixed-valence thiolate-bridged Cu(I)/Cu(II) cluster complexes.

H. Schugar, M. Potenza, M. Brader, 2002, Inorganic chemistry.

Copper promoted reactions of the heterocyclic thioamide, 2-thiazolidinethione

E. Baker, B. Anderson, G. Gainsford, 1985 .

Copper(II)-Promoted Oxidation of Mercaptocarboxylic Acids. The Characterization of Disulfide- and Oxalate-Containing Products. Crystal Structures of ((Cu(bipy)(2,2′-dtdp))n)·3nH2O and ((Cu(bipy)(3,3′-dtdp))n)·2nH2O (bipy: 2,2′-Bipyrid

E. Baker, M. Brader, David A. Lewandoski, 1990 .

The copper promoted oxidation of 1-methylimidazoline-2(3H)-thione to bis(1-methylimidazol-2-yl)sulfide

G. Gainsford, M. Brader, E. Ainscough, 1991 .

Hybrid insulin cocrystals for controlled release delivery

Allen H. Pekar, D. Flora, R. Chance, 2002, Nature Biotechnology.

Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure.

M. Ward, C. Yip, M. Brader, 1998, Biophysical journal.

Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering.

Michael F. Drenski, R. W. Alston, W. Reed, 2013, Analytical biochemistry.

Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity.

John P. Gabrielson, G. Winter, J. Carpenter, 2007, Journal of pharmaceutical sciences.

Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product.

Damian Houde, Pavel Landsman, Shujun Bai, 2016, Journal of pharmaceutical sciences.

Structural and morphological characterization of ultralente insulin crystals by atomic force microscopy: evidence of hydrophobically driven assembly.

M. Ward, C. Yip, M. Brader, 1998, Biophysical journal.

Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.

Steven Lantz, Pavel Landsman, Shujun Bai, 2015, Molecular pharmaceutics.

Insulin hexamers: new conformations and applications.

M. Dunn, M. Brader, Michael F. Dunn, 1991, Trends in biochemical sciences.

Effects of surface hydrophobicity on the structural properties of insulin

A. Kriauciunas, V. J. Chen, M. Brader, 1997 .

Effects of Non-Covalent Self-Association on the Subcutaneous Absorption of a Therapeutic Peptide

M. Brader, H. Havel, Kevin A. Destrampe, 1998, Pharmaceutical Research.

Spectroscopic signatures of the T to R conformational transition in the insulin hexamer.

M. Roy, M. Dunn, N. Kaarsholm, 1989, Journal of Biological Chemistry.

Insulin stabilizes copper(II)-thiolate ligation that models blue copper proteins

M. Dunn, M. Brader, 1990 .

Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies: Differential Scanning Calorimetry, Isothermal Chemical Denaturation, and Intrinsic Fluorescence with Concomitant Static Light Scattering.

Deniz B. Temel, P. Landsman, M. Brader, 2016, Methods in enzymology.

E. P. Schan, N. O. Whittington, L. W. Cannon, 1997 .

ZINC COORDINATION, ASYMMETRY, AND ALLOSTERY OF THE HUMAN INSULIN HEXAMER

M. Brader, 1997 .

Calcium binding to a factor ix Fc fusion protein and effects on higher-order structure.

S. Berkowitz, M. Brader, Shufeng Bai, 2011, Journal of pharmaceutical sciences.